In order to achieve treatment-free remission, which has become a key evaluation criterion for CML therapies, the search continues for drugs that efficiently eliminate LSCs, cells which are refractory to standard therapies mainly due to differing BCR-ABL1-independent mechanisms [27]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.